Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lyell Immunopharma (LYEL) Assets Average (2021 - 2025)

Historic Assets Average for Lyell Immunopharma (LYEL) over the last 5 years, with Q3 2025 value amounting to $396.7 million.

  • Lyell Immunopharma's Assets Average fell 3769.08% to $396.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $396.7 million, marking a year-over-year decrease of 3769.08%. This contributed to the annual value of $620.4 million for FY2024, which is 2646.98% down from last year.
  • Per Lyell Immunopharma's latest filing, its Assets Average stood at $396.7 million for Q3 2025, which was down 3769.08% from $407.6 million recorded in Q2 2025.
  • Lyell Immunopharma's 5-year Assets Average high stood at $1.2 billion for Q3 2021, and its period low was $396.7 million during Q3 2025.
  • For the 5-year period, Lyell Immunopharma's Assets Average averaged around $805.2 million, with its median value being $815.2 million (2023).
  • In the last 5 years, Lyell Immunopharma's Assets Average tumbled by 1734.47% in 2023 and then crashed by 3953.77% in 2025.
  • Over the past 5 years, Lyell Immunopharma's Assets Average (Quarter) stood at $1.2 billion in 2021, then fell by 17.67% to $957.4 million in 2022, then dropped by 19.31% to $772.5 million in 2023, then decreased by 28.15% to $555.0 million in 2024, then fell by 28.53% to $396.7 million in 2025.
  • Its Assets Average stands at $396.7 million for Q3 2025, versus $407.6 million for Q2 2025 and $460.3 million for Q1 2025.